Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers
- PMID: 17224709
- DOI: 10.1097/00004714-200702000-00005
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers
Abstract
This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol. Single-dose pharmacokinetics of metoprolol were measured before and after 17 days of treatment with escitalopram 20 mg/d, duloxetine 60 mg/d, or sertraline 100 mg/d in young healthy male and female participants. The outcome measures were changes in metoprolol peak plasma levels, area under the plasma concentration-time curve, and clearance. The results were tested using paired t tests and independent t tests. The addition of each drug produced statistically significant changes in metoprolol pharmacokinetics. The rank order for the change in metoprolol area under the plasma concentration-time curve was duloxetine (180%) > escitalopram (89%) > sertraline (48% and 67%). Compared with sertraline, duloxetine produced statistically significantly larger changes in metoprolol pharmacokinetic parameters. The changes produced by escitalopram and sertraline were not statistically different.
Similar articles
-
[Interactions between metoprolol and antidepressants].Tidsskr Nor Laegeforen. 2011 Sep 20;131(18):1777-9. doi: 10.4045/tidsskr.11.0143. Tidsskr Nor Laegeforen. 2011. PMID: 21946596 Review. Norwegian.
-
An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.Drug Metab Dispos. 2008 Dec;36(12):2484-91. doi: 10.1124/dmd.108.021527. Epub 2008 Sep 22. Drug Metab Dispos. 2008. PMID: 18809731 Clinical Trial.
-
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.Clin Pharmacol Ther. 2003 Mar;73(3):170-7. doi: 10.1067/mcp.2003.28. Clin Pharmacol Ther. 2003. PMID: 12621382
-
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.J Clin Psychopharmacol. 2005 Dec;25(6):552-60. doi: 10.1097/01.jcp.0000185429.10053.c8. J Clin Psychopharmacol. 2005. PMID: 16282837
-
Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.J Psychiatr Pract. 2008 Nov;14(6):368-78. doi: 10.1097/01.pra.0000341891.43501.6b. J Psychiatr Pract. 2008. PMID: 19057238 Review.
Cited by
-
Acute liver injury secondary to sertraline.BMJ Case Rep. 2013 Sep 26;2013:bcr2013201022. doi: 10.1136/bcr-2013-201022. BMJ Case Rep. 2013. PMID: 24072839 Free PMC article.
-
Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.Clin Pharmacokinet. 2011 Aug;50(8):519-30. doi: 10.2165/11592620-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21740075
-
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.Acta Oncol. 2010 Apr;49(3):305-12. doi: 10.3109/02841860903575273. Acta Oncol. 2010. PMID: 20156115 Free PMC article.
-
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.JAMA. 2013 Apr 3;309(13):1359-67. doi: 10.1001/jama.2013.2813. JAMA. 2013. PMID: 23549581 Free PMC article. Clinical Trial.
-
PharmGKB summary: sertraline pathway, pharmacokinetics.Pharmacogenet Genomics. 2020 Feb;30(2):26-33. doi: 10.1097/FPC.0000000000000392. Pharmacogenet Genomics. 2020. PMID: 31851125 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
